Prostate Cancer Trials Working Group 3 (PCWG3) shows the qualification criteria for treatment (65): mCRPC with changes described in PET-PSMA, progression after application of at least one cycle of chemotherapy, progression after application of new androgen receptor-targeting agents (ARTA) (abirateron or enzalutamid), progression after application of Radium-223 or without medical indication for usage of this substance, recommendation for 177Lu PSMA-617 RLT in interdisciplinary proceeding. Here, FOLH1 is linked to prostate cancer.